[1]
Falchi, L., Baron, J.M., Orlikowski, C.A. and Ferrajoli, A. 2016. BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases. 8, (Feb. 2016), e2016011. DOI:https://doi.org/10.4084/mjhid.2016.011.